Combination Therapy for Cancer Metastases: A Promising New Approach

Strategic Insights -

Researchers at the University of Cincinnati have developed a novel combination therapy for treating cancer metastases, which shows promise in addressing the long-standing challenge of treating the secondary growths that often accompany primary tumors. The therapy, which incorporates a combination of vascularization and/or tissue remodeling inhibitors, suppressors of oxidative metabolism, and ion homeostasis modulators, aims to target the molecular mechanisms of metastasis rather than the primary tumor or destination tissue. This innovative approach has the potential to improve the prognosis and outcome for patients with metastatic cancers.

Key Takeaways:

  • The new therapy combines three types of inhibitors to target the molecular mechanisms of metastasis: vascularization and/or tissue remodeling inhibitors, suppressors of oxidative metabolism, and ion homeostasis modulators.
  • The therapy is designed to treat cancer metastases in a subject in need thereof, with the method comprising administering a combination therapy comprising a vascularization and/or tissue remodeling inhibitor, a suppressor of oxidative metabolism, and an ion homeostasis modulator.
  • The vascularization and/or tissue remodeling inhibitor can be a broad-spectrum vascular endothelial growth factor receptor (VEGFR) inhibitor or a matrix metalloproteinase (MMP) inhibitor, specifically mentioning pazopanib and marimastat as examples.
  • The suppressor of oxidative metabolism can be selected from the group consisting of dimethyl sulfoxide (DMSO), atovaquone, N-acetylcysteine (NAC), taurine, and combinations thereof, with DMSO and atovaquone being specifically mentioned.
  • The ion homeostasis modulator can be an NKCC inhibitor or a copper chelator, specifically mentioning bumetanide and tetrathiomolybdate as examples.
  • The combination therapy can be administered enterally or parenterally, with parenteral administration able to include intravenous or intratumoral administration.

Statistics:

  • The patent application was filed on January 6, 2025.
  • The patent application was made available online on July 10, 2025.
  • The invention relates to methods and combination therapies for the treatment of cancer metastases.
  • The therapy targets the molecular mechanisms of metastasis rather than the primary tumor or destination tissue.

Sources:

  • Weber, Georg F. Combination Therapy For The Treatment Of Cancer Metastases. U.S. Patent Application Number 20250221991, filed January 6, 2025 and posted July 10, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(20250221991)&db=US-PGPUB&type=ids